Author:
Hellings P.W.,Fokkens W.J.,Orlandi R.,Adriaensen G.F.,Alobid I.,Baroody F.M.,Bjermer L.,Senior B.A.,Cervin A.,Cohen N.A.,Constantinidis J.,De Corso E.,Desrosiers M.,Diamant Z.,Douglas R.G.,Gane S.,Gevaert P.,Han J.K.,Harvey R.J.,Hopkins C.,Kern R.C.,Landis B.N.,Lee J.T.,Lee S.E.,Leunig A.,Lund V.J.,Manuel-Sprekelsen B.,Mullol J.,Philpott C.,Prokopakis E.,Reitsma S.,Ryan D.,Salmi S.,Scadding G.,Schlosser R.J.,Steinsvik A.,Tomazic P.V.,Van Staeyen E.,Van Zele T.,Vanderveken O.,Viskens A-S.,Conti D.,Wagenmann M.
Abstract
Chronic rhinosinusitis (CRS) is known to affect around 5 % of the total population, with major impact on the quality of life of those severely affected (1). Despite a substantial burden on individuals, society and health economies, CRS often remains underdiagnosed, under-estimated and under-treated (2). International guidelines like the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) (3) and the International Consensus statement on Allergy and Rhinology: Rhinosinusitis 2021 (ICAR) (4) offer physicians insight into the recommended treatment options for CRS, with an overview of effective strategies and guidance of diagnosis and care throughout the disease journey of CRS.
Subject
Otorhinolaryngology,General Medicine